All news articles for August 2022


US government provides funds to boost continuous bioprocessing

By Ben Hargreaves

Despite continuous bioprocessing being talked about as the future of manufacturing in biologics for years, this has not become reality. However, in recent years, the US government has begun to dedicate funds to intensify the production of biologics.


AstraZeneca gains first approval for Evusheld as COVID-19 treatment

By Rachel Arthur

AstraZeneca's long-acting antibody combination Evusheld has been approved in Japan for both prevention (pre-exposure prophylaxis) and treatment of symptomatic disease caused by SARS-CoV-2 infection: marking the first global marketing approval of...


Philadelphia’s CGT sector highlights future talent needs

By Rachel Arthur

Employment in Greater Philadelphia among cell and gene therapy companies has more that doubled since 2019, while employees at contract manufacturing organizations have grown by nearly 40%. Continuing to build the workforce will be crucial as the area...


WHO recommends two mAbs in fight against Ebola

By Rachel Arthur

The World Health Organization (WHO) has published its first guidelines for Ebola virus disease therapeutics, issuing ‘strong recommendations’ for the use of two monoclonal antibodies.


Pfizer and BioNTech submit Omicron booster EUA application to US FDA

By Rachel Arthur

Pfizer and BioNTech have completed their application to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine: saying they stand ready to start shipping...


WHO issues latest recommendations for COVID-19 booster doses

By Rachel Arthur

The WHO has updated its advice on COVID-19 booster doses: including recommendations on which groups should receive a second booster shot and how countries should plan around the upcoming availability of variant-specific vaccines.

Photo Credit: GettyImages/Morsa Images

EMA evaluating Skycovion COVID-19 vaccine

By Jane Byrne

EMA has begun its review of the conditional marketing authorization application from South Korean developer, SK biosciences, for its COVID-19 vaccine, Skycovion, a recombinant protein-based vaccine with adjuvant from GSK.

Follow us


View more